BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24950821)

  • 1. Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for (125)I brachytherapy.
    Karlsson M; Nilsson J; Lundell M; Carlsson Tedgren A
    Brachytherapy; 2014; 13(6):651-6. PubMed ID: 24950821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy.
    Thomson RM; Taylor RE; Rogers DW
    Med Phys; 2008 Dec; 35(12):5530-43. PubMed ID: 19175111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
    Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
    Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
    Thomson RM; Rogers DW
    Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
    Lesperance M; Martinov M; Thomson RM
    Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced Collapsed cone Engine dose calculations in tissue media for COMS eye plaques loaded with I-125 seeds.
    Morrison H; Menon G; Larocque MP; van Veelen B; Niatsetski Y; Weis E; Sloboda RS
    Med Phys; 2018 Jul; 45(7):3349-3360. PubMed ID: 29729009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry for 125I seed (model 6711) in eye plaques.
    Chiu-Tsao ST; Anderson LL; O'Brien K; Stabile L; Liu JC
    Med Phys; 1993; 20(2 Pt 1):383-9. PubMed ID: 8497229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.
    Asadi S; Vaez-zadeh M; Masoudi SF; Rahmani F; Knaup C; Meigooni AS
    J Appl Clin Med Phys; 2015 Sep; 16(5):344–357. PubMed ID: 26699318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROPES eye plaque brachytherapy dosimetry for two models of (103)Pd seeds.
    Saidi P; Sadeghi M; Shirazi A; Tenreiro C
    Australas Phys Eng Sci Med; 2011 Jun; 34(2):223-31. PubMed ID: 21452056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric study of the 15 mm ROPES eye plaque.
    Granero D; Pérez-Calatayud J; Ballester F; Casal E; de Frutos JM
    Med Phys; 2004 Dec; 31(12):3330-6. PubMed ID: 15651616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques.
    Yang YM; Chow PE; McCannel TA; Lamb JM
    Med Phys; 2019 Feb; 46(2):1006-1011. PubMed ID: 30554429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs.
    Melhus CS; Rivard MJ
    Med Phys; 2008 Jul; 35(7):3364-71. PubMed ID: 18697560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).
    Acar H; Chiu-Tsao ST; Ozbay I; Kemikler G; Tuncer S
    Med Phys; 2013 Jan; 40(1):011708. PubMed ID: 23298078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant.
    Zhang H; Martin D; Chiu-Tsao ST; Meigooni A; Thomadsen BR
    Brachytherapy; 2010; 9(4):362-72. PubMed ID: 20116342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose characteristics of Au-198 eye brachytherapy applicator: A Monte Carlo study.
    Kamrani S; Aghamiri SMR; Hashemi S
    Appl Radiat Isot; 2021 Oct; 176():109866. PubMed ID: 34293507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monte Carlo dosimetry for I125 and Pd103 eye plaque brachytherapy.
    Thomson RM; Taylor REP; Rogers DWO
    Med Phys; 2008 Dec; 35(12):5530-5543. PubMed ID: 28525130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Episcleral eye plaque dosimetry comparison for the Eye Physics EP917 using Plaque Simulator and Monte Carlo simulation.
    Zimmermann LW; Amoush A; Wilkinson DA
    J Appl Clin Med Phys; 2015 Nov; 16(6):226-239. PubMed ID: 26699577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
    Johnson JE; Deufel CL; Furutani KM
    Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved treatment planning for COMS eye plaques.
    Astrahan MA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.